Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical DevelopmentMagdalena Ślusarczyk, Christopher McGuigan, Essam Ghazaly et al.|Journal of Medicinal Chemistry|2014Cited by 151
Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survivalEssam Ghazaly, Sarah P. Blagden, Magdalena Ślusarczyk et al.|Molecular Cancer Therapeutics|2015Cited by 9
ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.Essam Ghazaly, Sarah P. Blagden, Simon Joel et al.|Journal of Clinical Oncology|2013Cited by 8
Abstract CT401: NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survivalEssam Ghazaly, Sarah P. Blagden, Magdalena Ślusarczyk et al.|Cancer Research|2014Cited by 6
Abstract CT028: First-in-human phase I study of the nucleotide analogue NUC-3373 designed to overcome fluoropyrimidine drug resistance mechanismsSarah P. Blagden, Essam Ghazaly, Michaela Serpi et al.|Cancer Research|2016Cited by 5